埃弗雷斯特医药公司的性结肠炎药物VELSIPITY被香港卫生部门接受审查. Everest Medicines' ulcerative colitis drug, VELSIPITY, is accepted for review by Hong Kong's health department.

埃弗雷斯特医药公司的新药申请VELSIPITY (etrasimod) 治疗性结肠炎, 已被香港卫生部接受. Everest Medicines' New Drug Application for VELSIPITY (etrasimod), an oral, once-daily treatment for ulcerative colitis, has been accepted by Hong Kong's Department of Health. 该药物已经在美国和欧盟得到批准,对未接受其他治疗的病人来说,它显示了希望。 The drug, already approved in the U.S. and EU, shows promise for patients who have not responded to other treatments. 在成功进行第三阶段试验的基础上,威利普特基金会旨在为中国和香港的更多病人提供救济。 Based on successful Phase 3 trials, VELSIPITY aims to provide relief to more patients in China and Hong Kong.